Dr. Jim Wu is founder, chairman and CEO of Shanghai Ark Biopharmaceutical Co. (Ark Bio). Ark Bio is a clinical stage biopharmaceutical company, focusing on discovery and development of innovative drugs for treatment of respiratory and lung diseases, and pediatric diseases. Its R&D pipeline covers full cycle of acute, chronic and end-stage respiratory and lung diseases, especially in the areas of respiratory viral infection, pulmonary fibrosis and pediatric diseases, with 10 drug candidates. Among them, ziresovir has a breakthrough designation, conducts the pivotal clinical trial with a promise to become first drug to treat respiratory syncytial virus infection globally.
Dr. Wu obtained his BSc from University of Science and Technology of China, his PhD from Brown University, and conducted postdoctoral research at Harvard Medical School. He worked at Schering-Plough, Valeant Pharmaceuticals, and Roche with various R&D management and leadership roles. He has co-authored >70 scientific papers, served as a member of editorial advisory board of Antimicrobial Agents and Chemotherapy, was an adjunct professor at Fudan University School of Pharmacy and Shanghai Medical College.